Cellectis S.A.
CLLS
$1.26
$0.0352.87%
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
--
Headlines
3/7/2025
-
GuruFocus
3/7/2025
-
Globe Newswire
3/6/2025
-
Globe Newswire
2/28/2025
-
MarketBeat
2/24/2025
-
GuruFocus
2/24/2025
-
Globe Newswire
2/19/2025
-
MarketBeat
2/19/2025
-
MarketBeat
2/16/2025
-
MarketBeat
2/4/2025
-
Globe Newswire
2/2/2025
-
MarketBeat
1/26/2025
-
Ticker Report
1/24/2025
-
MarketBeat
1/18/2025
-
MarketBeat
1/18/2025
-
Ticker Report
1/16/2025
-
MarketBeat
1/15/2025
-
SeekingAlpha.com: All News
1/15/2025
-
Seeking Alpha - Healthcare
1/15/2025
-
TipRanks Financial Blog
1/15/2025
-
The Fly
1/8/2025
-
Globe Newswire
1/8/2025
-
Ticker Report
1/8/2025
-
MarketBeat
1/7/2025
-
Zacks Investment Research
1/5/2025
-
Ticker Report
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Monday, November 4, 2024
Period Date
Monday, September 30, 2024
Next Filing
End of April (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
33 1 81 69 16 00
Address
8, rue de la Croix Jarry
Paris, 75013
Paris, 75013
Country
Year Founded
Business Description
Sector
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company...
more
